Orion OYJ (OTCMKTS:ORINY) Shares Gap Up – What’s Next?

Shares of Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) gapped up prior to trading on Tuesday . The stock had previously closed at $33.6250, but opened at $35.15. Orion OYJ shares last traded at $35.15, with a volume of 233 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ORINY shares. Zacks Research cut Orion OYJ from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Nordea Equity Research upgraded Orion OYJ from a “hold” rating to a “buy” rating in a research report on Monday, October 6th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Orion OYJ Price Performance

The stock has a fifty day moving average of $36.43 and a two-hundred day moving average of $37.30. The company has a current ratio of 1.99, a quick ratio of 1.19 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $9.92 billion, a price-to-earnings ratio of 28.35 and a beta of 0.04.

Orion OYJ (OTCMKTS:ORINY) last announced its earnings results on Tuesday, October 28th. The company reported $0.40 earnings per share for the quarter. Orion OYJ had a return on equity of 31.36% and a net margin of 19.33%.The company had revenue of $494.69 million during the quarter. As a group, equities research analysts forecast that Orion OYJ Unsponsored ADR will post 1.18 earnings per share for the current year.

Orion OYJ Dividend Announcement

The company also recently disclosed a dividend, which was paid on Friday, November 7th. Investors of record on Friday, October 17th were given a $0.2418 dividend. This represents a yield of 127.0%. The ex-dividend date was Thursday, October 16th. Orion OYJ’s dividend payout ratio (DPR) is presently 26.61%.

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.